StockData
Haemonetics Corp logo

Haemonetics Corp (HAE) company profile

HAENYSESurgical & Medical Instruments & ApparatusFiscal year ends April 3
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 27, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3073% above fair value
$120.92−0.42 (-0.35%)

Close on Nov 17, 2026Market cap $5.50BP/E 59.0Yield –

About Haemonetics

Surgical & Medical Instruments & Apparatus, SIC 3841

Haemonetics Corporation is a medical technology provider that supplies devices, software, and consumables to the healthcare sector. The company manages three primary segments: Plasma, Blood Center, and Hospital. Its Plasma division offers automated collection equipment and donor management software for source plasma facilities. The Blood Center unit provides automated apheresis systems to collect and process platelets, plasma, and red cells. Its Hospital segment delivers vascular closure devices, sensor-guided guidewires, esophageal protection tools, diagnostic hemostasis analyzers, surgical cell salvage systems, and transfusion management software. Customers comprise biopharmaceutical companies, blood collection centers, hospitals, group purchasing organizations, and health agencies.

The company sells products in approximately 90 countries via a direct sales force and third-party distributors across about 87 countries. Consumable manufacturing occurs mainly in North America and Malaysia, with contract partners producing components in Japan, Singapore, Thailand, Indonesia, and the Philippines. Equipment production takes place in Malaysia, Australia, and the United States. The text does not identify the company's corporate headquarters.

Summary of the business section of Haemonetics's latest annual report, written by StockData.

Company profile

Company

Legal name
Haemonetics Corp
Founded
1971
Headquarters
Boston, MA
Address
125 Summer Street 02110
Phone
(781) 848-7100
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Massachusetts
Fiscal year ends
April 3
Auditor
Ernst & Young LLP, Boston, Massachusetts

Stock & identifiers

Ticker
HAE
Exchange
NYSE
IPO date
May 10, 1991
Shares outstanding
45M, Jul 31, 2026
Public float
$2.23B, Sep 27, 2025
Filer category
Large accelerated filer
Stock splits
2-for-1, Dec 3, 2012; 2-for-1, Jan 11, 1993
SEC CIK
313143
CUSIP
405024100
ISIN
US4050241003
FIGI
BBG000C7TF41
Share class FIGI
BBG001S6QB64
LEI
549300ZEL6TXZS6F5F95
EIN
04-2882273

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Simon, ChristopherPresident & CEO, Director444,704
Farris Maryanne MaunsellVP, Chief Accounting Officer5,828
Roy GalvinEVP, Chief Commercial Officer39,805
Laurie A. MillerSVP, Human Resources40,987
Frank ChanEVP, Chief Operating Officer5,401
James DAreccaEVP, Chief Financial Officer54,444
Michelle L. BasilEVP and General Counsel68,829
Mark W. KrollDirector27,295
Martin D. MadausDirector2,538
Ellen M. ZaneDirector21,911
Claire PomeroyDirector19,410
Diane M. BryantDirector9,664
Lloyd Emerson JohnsonDirector15,471
Robert E. AbernathyDirector27,519
Michael J. CoyleDirector17,932
Charles J. DockendorffDirector25,041

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2026$12.04M$8.12M$3.35M$48$65
FY2025$10.72M$1.35M$2.48M$63$121
FY2024$11.55M$10.18M$2.80M$85$129
FY2023$10.69M$18.08M$2.40M$82$137
FY2022$8.70M-$2.35M$2.87M$63$167
FY2021$8.63M$6.61M$1.95M$111$175

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2026

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Christopher A. Simon
President and Chief Executive Officer
$1.10M–$7.56M$1.50M$1.83M$43.49K$12.04M+12%
James C. D'Arecca
Executive Vice President, Chief Financial Officer
$603.70K–$1.84M$499.99K$648.86K$28.99K$3.62M+22%
Michelle L. Basil
Executive Vice President, General Counsel
$558.78K–$1.75M$474.98K$599.77K$26.73K$3.41M+22%
Frank W. Chan
Executive Vice President, Chief Operating Officer
$518.26K$350.00K$1.47M$400.00K$574.06K$21.39K$3.34M–
Roy Galvin
Executive Vice President, Chief Commercial Officer
$550.21K–$1.47M$400.00K$586.96K$28.82K$3.04M+38%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Corporate history

Events identified from SEC filings

See a number that looks wrong?